Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,581 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $43.01, for a total value of $498,098.81. Following the sale, the chief financial officer now directly owns 107,789 shares in the company, valued at approximately $4,636,004.89. This trade represents a 9.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, February 4th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $38.92, for a total value of $450,732.52.
• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.44, for a total value of $283,039.64.
• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.98, for a total value of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $43.56 on Wednesday. Hims & Hers Health, Inc. has a one year low of $9.14 and a one year high of $46.01. The firm has a market capitalization of $9.52 billion, a price-to-earnings ratio of 99.01 and a beta of 1.35. The business has a 50-day simple moving average of $30.73 and a 200 day simple moving average of $23.58.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HIMS. Needham & Company LLC lifted their target price on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, January 6th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler lifted their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $25.13.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in the stock. SlateStone Wealth LLC boosted its stake in Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares during the last quarter. Blume Capital Management Inc. boosted its stake in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. Quest Partners LLC boosted its stake in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the last quarter. Harbour Investments Inc. boosted its stake in Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after purchasing an additional 833 shares during the last quarter. Finally, Stonekeep Investments LLC boosted its stake in Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after purchasing an additional 882 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.